Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dentsply Sirona (XRAY) Amortization of Deferred Charges (2016 - 2021)

Dentsply Sirona (XRAY) has disclosed Amortization of Deferred Charges for 11 consecutive years, with $2.0 million as the latest value for Q1 2021.

  • For the quarter ending Q1 2021, Amortization of Deferred Charges rose 100.0% year-over-year to $2.0 million, compared with a TTM value of $6.0 million through Mar 2021, up 81.82%, and an annual FY2020 reading of $5.0 million, up 66.67% over the prior year.
  • Amortization of Deferred Charges was $2.0 million for Q1 2021 at Dentsply Sirona, up from $1.6 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $2.0 million in Q1 2021 and bottomed at $600000.0 in Q2 2017.
  • Average Amortization of Deferred Charges over 5 years is $917647.1, with a median of $700000.0 recorded in 2017.
  • The sharpest move saw Amortization of Deferred Charges crashed 60.0% in 2017, then soared 128.57% in 2020.
  • Year by year, Amortization of Deferred Charges stood at $700000.0 in 2017, then soared by 42.86% to $1.0 million in 2018, then dropped by 10.0% to $900000.0 in 2019, then soared by 77.78% to $1.6 million in 2020, then increased by 25.0% to $2.0 million in 2021.
  • Business Quant data shows Amortization of Deferred Charges for XRAY at $2.0 million in Q1 2021, $1.6 million in Q4 2020, and $1.6 million in Q3 2020.